Vraylar (cariprazine) is not a controlled substance. The FDA prescribing information states this explicitly, and the Drug Enforcement Administration (DEA) does not place it on any schedule. You do not need a special prescription to obtain it, and pharmacies do not track it under controlled substance regulations.
Why Vraylar Is Not Controlled
The DEA schedules drugs based on their potential for abuse and dependence. Vraylar doesn’t meet either threshold. Its effects on the brain are fundamentally different from drugs that carry abuse risk. Rather than flooding dopamine receptors the way stimulants or opioids do, Vraylar works as a partial agonist, meaning it partially activates certain dopamine receptors while simultaneously blocking them from being overstimulated. This mechanism doesn’t produce a “high,” trigger cravings, or create the reward-seeking patterns associated with addictive substances.
Animal studies found no reward-seeking behavior with cariprazine, and long-term patient data confirmed no signs of abuse or physical dependence. In fact, Vraylar’s activity at dopamine D3 receptors may actually reduce reward-seeking and craving in people with substance use disorders, making it pharmacologically the opposite of a drug with abuse potential.
What Vraylar Is Used For
Vraylar is an atypical antipsychotic with a broader range of FDA-approved uses than many similar medications. It is currently approved for:
- Schizophrenia in adults and adolescents 13 and older
- Manic or mixed episodes of bipolar I disorder in adults and children 10 and older
- Bipolar depression (depressive episodes in bipolar I disorder) in adults
- Major depressive disorder in adults, as an add-on to antidepressants
Doses range from 1.5 mg to 6 mg once daily depending on the condition being treated. For bipolar depression and major depression, the maximum dose is lower, capping at 3 mg daily. For schizophrenia and manic episodes, doses can go up to 6 mg in adults.
How It Differs From Controlled Psychiatric Medications
Some psychiatric medications are controlled substances. Benzodiazepines (like lorazepam and alprazolam), stimulants (like amphetamine salts), and certain sleep medications are all DEA-scheduled because they carry real risks of dependence and misuse. These drugs typically work by either strongly boosting dopamine in reward pathways or enhancing calming brain chemicals in ways that create tolerance over time.
Vraylar’s partial agonist mechanism is a different story entirely. It modulates dopamine and serotonin activity without overwhelming those systems. This is the same general reason other atypical antipsychotics like aripiprazole, olanzapine, and quetiapine are also not classified as controlled substances (though quetiapine does see some off-label misuse). The class as a whole simply doesn’t produce the subjective effects that drive addiction.
Important Safety Warnings
Not being a controlled substance doesn’t mean Vraylar is free of serious risks. The medication carries two boxed warnings, the FDA’s most prominent safety alert. The first warns that antipsychotic drugs, including Vraylar, increase the risk of death in elderly patients with dementia-related psychosis. In clinical trials across this class of drugs, roughly 4.5% of drug-treated elderly patients with dementia died during a typical 10-week trial, compared to about 2.6% on placebo. Vraylar is not approved for dementia-related psychosis.
The second boxed warning addresses suicidal thoughts and behaviors. Because Vraylar is approved as an add-on for depression, the FDA requires a warning that antidepressant treatments can increase suicidal thinking in younger patients, particularly in the early weeks of treatment or after dose changes. Close monitoring during these periods is standard practice.
Vraylar also carries warnings about stroke risk in elderly patients with dementia and the movement disorder side effects common to antipsychotic medications. These are safety considerations your prescriber weighs when choosing this medication, but none of them relate to abuse or dependence risk. The drug requires a standard prescription, is refilled through normal pharmacy channels, and has no special dispensing restrictions.